Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05749055 · ClinicalTrials.gov registry record · Phase 2
ENCALM: A Study of ENX-102 as a Monotherapy Treatment in Patients With Generalized Anxiety Disorder
A Phase 2 study, sponsored by Engrail Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 252
- Enrollment target
NCT05749055 is a Phase 2 study that has completed, run by Engrail Therapeutics. The registered enrollment target is 252 participants.
The verdict
NCT05749055, a Phase 2 study, has completed, sponsored by Engrail Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 252 participants
- Enrollment target
Study Summary
The ENCALM trial is designed to evaluate the efficacy and safety of ENX-102 in patients diagnosed with generalized anxiety disorder (GAD)
Interventions
- DRUG Placebo
- DRUG ENX-102
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 252 participants |
| Start Date | 2023-07-03 |
| Est. Completion | 2025-09-18 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05749055
The ClinicalTrials.gov registry entry for NCT05749055 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 252 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Engrail Therapeutics, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05749055 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05749055 about?
NCT05749055 is a clinical study titled "ENCALM: A Study of ENX-102 as a Monotherapy Treatment in Patients With Generalized Anxiety Disorder". The ENCALM trial is designed to evaluate the efficacy and safety of ENX-102 in patients diagnosed with generalized anxiety disorder (GAD)
What is the current status of trial NCT05749055?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 252 participants. The study started on 2023-07-03. Estimated completion is 2025-09-18.
What interventions are being tested in trial NCT05749055?
The interventions under investigation include: Placebo (DRUG), ENX-102 (DRUG).
Who is sponsoring clinical trial NCT05749055?
This trial is sponsored by Engrail Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.